Content about Haemophilia

PRINCETON, N.J. — Novo Nordisk has launched a mobile app for hemophilia patients, the drug maker said.

HemaGo — available for iPhone, iPad and Android devices — is designed to track hemophilia treatment, bleeding episodes and life events, helping people with the condition and their caregivers monitor the details of treatment, including medications, dosing, bleeding information and the disease's effects on life events.

ALTAMONTE SPRINGS, Fla. — BioPlus Specialty Pharmacy has appointed a new person to head its bleeding disorders program, the company said Tuesday.

BioPlus announced the promotion of Shelley Moore to the position of national director of hemophilia. Moore already has served as head of the company's bleeding disorders program for Tennessee and has six years' nursing experience and a career specialty in bleeding disorders.

MONTVILLE, N.J. — Bayer HealthCare Pharmaceuticals and the World Federation of Hemophilia announced Thursday a three-year extension of Bayer’s sponsorship agreement with the WFH.

The agreement calls for Bayer to serve as the sole sponsor of the WFH’s International Hemophilia Training Centre program and provide support for other activities of the organiztion, such as its website and Congress. The program trains healthcare professionals in developing countries in diagnosis and management of hemophilia and related bleeding disorders.

PRINCETON, N.J. — Danish drug maker Novo Nordisk has received the Corporate Leadership Award from the National Hemophilia Foundation in response to its research and development efforts for the disease, the company said Friday.

Novo Nordisk president Jurek Gruhn accepted the award at the NHF’s Inaugural Spring Soiree Benefit in New York Thursday. Novo Nordisk makes NovoSeven RT (coagulation factor VIIa [recombinant], room temperature stable), used to treat hemophilia A and B.

PRINCETON, N.J. — Novo Nordisk has filed for approval of a treatment for a rare genetic bleeding disorder, the Danish drug maker said Wednesday.

The company submitted to the Food and Drug Administration its application for recombinant factor XIII compound, for congenital factor XIII deficiency. Current treatments for FXIII deficiency use products derived from human blood plasma, which carries the risk of contamination.

NEW YORK The Food and Drug Administration has approved a prefilled dual-chamber syringe made by Pfizer for treating hemophilia, Pfizer said.

The FDA approved the syringe for administering the drug Xyntha (antihemophilic factor [recombinant]) for hemophilia A. The drug is used to prevent and control bleeding episodes in patients.